Metropolis Healthcare share price: Shares of Metropolis Healthcare rose 5.02% to an intraday high of ₹2,150 per share on the National Stock Exchange (NSE) on Friday, September 19.
At around 3:04 pm, the stock was trading 4.01% higher at ₹2,129.20 per share.
Metropolis said in a regulatory filing on Thursday that the diagnostic chain has completed the acquisition of Kolhapur-based Ambika Pathology Laboratory through a business transfer agreement, its fourth acquisition in the last 10 months.
With the completion of this acquisition, Ambika Pathology has joined the Metropolis network.
The filing further states that the company plans to develop the newly acquired entity as a small-area reference laboratory, providing advanced and specialized diagnostic services to over 4,000 patients in Kolhapur and surrounding tier two and tier three cities.
This acquisition is a significant milestone in its “String of Pearls” strategy, which focuses on building strong regional clusters and expanding access to advanced diagnostics across India.
Commenting on the acquisition, Surendran Chemenkottil, Managing Director of Metropolis Healthcare Limited, said: “Our network expansion through both organic and inorganic growth is a strategic step towards reshaping the way diagnostic services are delivered in India. Kolhapur is a key healthcare hub, and the integration of Ambika Pathology Laboratory provides a strong foundation to serve patients and physicians more comprehensively.”
Ambika Pathology derives 75% of its revenue from B2C walk-in patients. Additionally, it operates 19 laboratories in Pune, Kolhapur, Sangli, Satara, Solapur, Nashik, and Ahmednagar, with 200 patient service centers and a growing franchise network.
Metropolis promoter and executive chairperson Ameera Shah said, “The acquisition of Ambika Pathology further strengthens our Western Maharashtra cluster and supports our ambition to make high-quality diagnostics accessible to more communities.”
In a separate regulatory filing this week, the diagnostic services provider incorporated healthcare technology firm Metropolis Quality Solutions Pvt Ltd as a wholly-owned subsidiary.
The stock declined 0.45% this week but has gained 32.04% in the six-month period. On a year-to-date basis, it is up 2.63%.
The stock hit a 52-week low of ₹1,315 on April 7, 2025, while it touched a one-year high of ₹2,318.30 per equity share on October 10, 2024.
As per NSE data, the total market capitalization of Metropolis Healthcare as of September 19, 2025 is ₹10,960.90 crore.
